Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

Author(s): Wolchok J, Hoos A, O’Day S, Weber JS, Hamid O, et al.


Purpose: Immunotherapeutic agents produce antitumor effects by inducing cancer-specific immune responses or by modifying native immune processes. Resulting clinical response patterns extend beyond those of cytotoxic agents and can manifest after an initial increase in tumor burden or the appearance of new lesions (progressive disease). Response Evaluation Criteria in Solid Tumors or WHO criteria, designed to detect early effects of cytotoxic agents, may not provide a complete assessment of immunotherapeutic agents. Novel criteria for the evaluation of antitumor responses with immunotherapeutic agents are required.

Similar Articles

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Author(s): Brahmer J, Tykodi S, Chow L, Hwu WJ, Topalian SL, et al.

Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung cancer

Author(s): Brahmer J, Reckamp KL, Baas P, Crinò L, Wilfried EE, et al.

Immunotherapy in the treatment of non-small cell lung cancer

Author(s): Sundar R, Soong R, Cho B, Brahmer J, Soo R

When progressive disease does not mean treatment failure: Reconsidering the criteria for progression

Author(s): Oxnard G, Morris M, Hodi F, Baker LH, Kris MG, et al.